This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blons, H. Articles by Laurent-Puig, P. Search for Related Content PubMed PubMed Citation Articles by Blons, H. Articles by Laurent-Puig, P.

Matrix Metalloproteinase 3 Polymorphism

A Predictive Factor of Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma

¹ Inserm 490 Laboratoire de Toxicologie Moléculaire, Université René Descartes ParisV, Paris; ² Inserm U525 Faculté de Médecine Hôpital Pitié-Salpétrière, Paris; ³ Service d’Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale, Paris; and ⁴ Pôle d’oncologie et de spécialité Hôpital Européen Georges Pompidou Assistance Publique–Hôpitaux de Paris, Paris, France

ABSTRACT

Purpose: Treatment of head and neck cancer often associates different therapeutic modalities, including surgery, radiotherapy, and chemotherapy. In an attempt to optimize therapeutics, the identification of molecular markers linked to response to chemotherapy remains important. Recently, the involvement of metalloproteinases in resistance to chemotherapy was suggested through their interaction with the Fas/Fas ligand pathway. Indeed metalloproteinases enhance Fas ligand shedding modulating chemotherapy efficiency. On the basis of these findings, we tested the existence of a correlation between response to chemotherapy and four metalloproteinase polymorphisms in a prospective series of 148 head and neck cancer patients.

Experimental Design: Patients were genotyped using automated fragment analysis and 5'-nuclease allelic discrimination assay. Response to chemotherapy was clinically assessed without knowledge of the genotype status.

Results: A significant relation between the metalloproteinase type 3 (MMP3) –1612insA polymorphism and response to chemotherapy was identified. Indeed, patients with the 6A/6A genotype responded more frequently (86%) to treatment as compared with patients with the 5A/6A (65%) or 5A/5A (55%) genotypes (P = 0.04). A multivariate analysis, including tumor stage, gender, TP53 mutations, and MMP3 polymorphism, showed that the 6A/6A genotype was an independent factor of response to 5-fluorouracil-cisplatin chemotherapy in head and neck cancer patients with an odds ratio of 6.7 as compared with the 5A/5A genotype.

Conclusions: This work showed that genotyping the MMP3 gene enhancer polymorphism –1612insA could help predict chemosensitivity in head and neck cancer patients.

This article has been cited by other articles:

				J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al. Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499. [Abstract] [Full Text] [PDF]

				F. Zinzindohoue, T. Lecomte, J.-M. Ferraz, A.-M. Houllier, P.-H. Cugnenc, A. Berger, H. Blons, and P. Laurent-Puig Prognostic Significance of MMP-1 and MMP-3 Functional Promoter Polymorphisms in Colorectal Cancer Clin. Cancer Res., January 15, 2005; 11(2): 594 - 599. [Abstract] [Full Text] [PDF]

				J. Zhang, X. Jin, S. Fang, Y. Li, R. Wang, W. Guo, N. Wang, Y. Wang, D. Wen, L. Wei, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma Carcinogenesis, December 1, 2004; 25(12): 2519 - 2524. [Abstract] [Full Text] [PDF]